Bal Pharma Limited (BALPHARMA.BO)
INR 106.04
(1.49%)
INR 106.04
(1.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.39 Billion INR | 12.43% |
| 2022 | 3.01 Billion INR | 7.87% |
| 2021 | 2.79 Billion INR | 13.26% |
| 2020 | 2.46 Billion INR | 47.28% |
| 2019 | 1.67 Billion INR | -24.0% |
| 2018 | 2.2 Billion INR | 6.09% |
| 2017 | 2.07 Billion INR | -7.27% |
| 2016 | 2.24 Billion INR | 15.11% |
| 2015 | 1.94 Billion INR | 4.1% |
| 2014 | 1.87 Billion INR | 4.63% |
| 2013 | 1.78 Billion INR | 20.93% |
| 2012 | 1.47 Billion INR | 5.89% |
| 2011 | 1.39 Billion INR | 22.06% |
| 2010 | 1.14 Billion INR | 7.73% |
| 2009 | 1.06 Billion INR | 2.54% |
| 2008 | 1.03 Billion INR | 20.83% |
| 2007 | 857.35 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 743.58 Million INR | -21.42% |
| 2023 Q1 | 701.65 Million INR | -12.23% |
| 2023 Q2 | 925.42 Million INR | 31.89% |
| 2023 Q3 | 816.63 Million INR | -11.76% |
| 2023 Q4 | 946.26 Million INR | 15.87% |
| 2023 FY | 3.39 Billion INR | 12.43% |
| 2022 FY | 3.01 Billion INR | 7.87% |
| 2022 Q4 | 799.41 Million INR | 4.34% |
| 2022 Q3 | 766.18 Million INR | 1.74% |
| 2022 Q2 | 753.07 Million INR | 8.34% |
| 2022 Q1 | 695.09 Million INR | -4.17% |
| 2021 Q4 | 725.33 Million INR | 4.87% |
| 2021 Q3 | 691.66 Million INR | 2.97% |
| 2021 Q2 | 671.71 Million INR | -5.16% |
| 2021 FY | 2.79 Billion INR | 13.26% |
| 2021 Q1 | 708.25 Million INR | 5.35% |
| 2020 Q2 | 645.6 Million INR | 23.85% |
| 2020 FY | 2.46 Billion INR | 47.28% |
| 2020 Q3 | 630.28 Million INR | -2.37% |
| 2020 Q4 | 672.26 Million INR | 6.66% |
| 2020 Q1 | 521.29 Million INR | 71.75% |
| 2019 FY | 1.67 Billion INR | -24.0% |
| 2019 Q2 | 449.87 Million INR | -8.49% |
| 2019 Q1 | 491.62 Million INR | -3.0% |
| 2019 Q3 | 431.72 Million INR | -4.03% |
| 2019 Q4 | 303.52 Million INR | -29.7% |
| 2018 Q4 | 506.85 Million INR | -5.38% |
| 2018 Q2 | 574.82 Million INR | 7.31% |
| 2018 FY | 2.2 Billion INR | 6.09% |
| 2018 Q1 | 535.67 Million INR | -9.06% |
| 2018 Q3 | 535.67 Million INR | -6.81% |
| 2017 FY | 2.07 Billion INR | -7.27% |
| 2017 Q4 | 589.06 Million INR | 0.0% |
| 2016 Q3 | 586.47 Million INR | -11.48% |
| 2016 FY | 2.24 Billion INR | 15.11% |
| 2016 Q4 | 643.46 Million INR | 9.72% |
| 2016 Q2 | 662.5 Million INR | 48.48% |
| 2016 Q1 | 446.18 Million INR | -18.6% |
| 2015 Q4 | 548.12 Million INR | 12.72% |
| 2015 FY | 1.94 Billion INR | 4.1% |
| 2015 Q1 | 548.12 Million INR | 5.28% |
| 2015 Q2 | 569.83 Million INR | 3.96% |
| 2015 Q3 | 486.25 Million INR | -14.67% |
| 2014 Q1 | 423.4 Million INR | -13.72% |
| 2014 Q4 | 520.64 Million INR | 21.24% |
| 2014 Q3 | 429.42 Million INR | -13.79% |
| 2014 FY | 1.87 Billion INR | 4.63% |
| 2014 Q2 | 498.09 Million INR | 17.64% |
| 2013 Q1 | 377.02 Million INR | -11.95% |
| 2013 Q4 | 490.72 Million INR | 10.89% |
| 2013 FY | 1.78 Billion INR | 20.93% |
| 2013 Q2 | 478.46 Million INR | 26.91% |
| 2013 Q3 | 442.51 Million INR | -7.51% |
| 2012 Q2 | 397.45 Million INR | 32.53% |
| 2012 Q1 | 299.89 Million INR | -25.6% |
| 2012 Q3 | 353.61 Million INR | -11.03% |
| 2012 Q4 | 428.18 Million INR | 21.09% |
| 2012 FY | 1.47 Billion INR | 5.89% |
| 2011 Q3 | 363.86 Million INR | 4.98% |
| 2011 Q4 | 403.09 Million INR | 10.78% |
| 2011 FY | 1.39 Billion INR | 22.06% |
| 2011 Q2 | 346.59 Million INR | 0.0% |
| 2010 FY | 1.14 Billion INR | 7.73% |
| 2009 FY | 1.06 Billion INR | 2.54% |
| 2008 FY | 1.03 Billion INR | 20.83% |
| 2007 FY | 857.35 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.301% |
| NATCO Pharma Limited | 40.02 Billion INR | 91.524% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 67.735% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -30.85% |
| Achyut Healthcare Limited | 61.36 Million INR | -5427.54% |
| Ajanta Pharma Limited | 42.08 Billion INR | 91.94% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.322% |
| Alpa Laboratories Limited | 1.08 Billion INR | -211.958% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 94.45% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 73.816% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.818% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 28.347% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 55.96% |
| Brooks Laboratories Limited | 794.86 Million INR | -326.766% |
| Divi's Laboratories Limited | 78.45 Billion INR | 95.676% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.785% |
| Eris Lifesciences Limited | 20.09 Billion INR | 83.116% |
| FDC Limited | 19.42 Billion INR | 82.541% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 97.128% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 85.143% |
| Granules India Limited | 45.06 Billion INR | 92.472% |
| Gufic Biosciences Limited | 8.06 Billion INR | 57.948% |
| Hester Biosciences Limited | 3.04 Billion INR | -11.385% |
| Indoco Remedies Limited | 17.89 Billion INR | 81.043% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 73.517% |
| Ipca Laboratories Limited | 76.22 Billion INR | 95.55% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -62.538% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -572.768% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -225.125% |
| Laurus Labs Limited | 50.01 Billion INR | 93.218% |
| Lupin Limited | 200.1 Billion INR | 98.305% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.718% |
| Medicamen Biotech Limited | 1.79 Billion INR | -89.185% |
| Medico Remedies Limited | 1.44 Billion INR | -134.073% |
| Megasoft Limited | 373.95 Million INR | -807.118% |
| Piramal Pharma Limited | 81.71 Billion INR | 95.849% |
| RPG Life Sciences Limited | 5.82 Billion INR | 41.72% |
| Sigachi Industries Limited | 3.98 Billion INR | 14.973% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -349.028% |
| Unichem Laboratories Limited | 16.57 Billion INR | 79.533% |
| Wanbury Limited | 5.75 Billion INR | 41.072% |
| Windlas Biotech Limited | 6.3 Billion INR | 46.237% |
| ZIM Laboratories Limited | 3.67 Billion INR | 7.676% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.217% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 70.535% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 19.469% |
| Strides Pharma Science Limited | 40.51 Billion INR | 91.627% |
| Venus Remedies Limited | 5.91 Billion INR | 42.646% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 81.315% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 79.857% |
| Shilpa Medicare Limited | 11.51 Billion INR | 70.544% |
| Aarti Drugs Limited | 25.28 Billion INR | 86.585% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 83.991% |
| Suven Life Sciences Limited | 116.92 Million INR | -2801.073% |
| Ind-Swift Limited | 5.02 Billion INR | 32.489% |
| Valiant Laboratories Limited | 1.82 Billion INR | -86.326% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 90.264% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 72.608% |
| Themis Medicare Limited | 3.81 Billion INR | 11.143% |
| Hikal Limited | 17.84 Billion INR | 80.992% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.801% |
| Sequent Scientific Limited | 13.69 Billion INR | 75.235% |
| Novartis India Limited | 3.35 Billion INR | -1.238% |
| Wockhardt Limited | 27.89 Billion INR | 87.837% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 94.939% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -747.301% |
| Neuland Laboratories Limited | 15.58 Billion INR | 78.235% |
| Morepen Laboratories Limited | 17.01 Billion INR | 80.068% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -119.741% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 7.97% |